Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

Inclusion Criteria: * Diagnosis of breast cancer, received chemotherapy, and scheduled to receive 4 to 6 weeks of radiation therapy (radiation protocol of 42 Gy+) * Area to be irradiated representing 1-10% of total body surface area (TBSA) * Able and willing to sign protocol consent form * Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes * Able and willing to have photographs of the affected area taken regularly Exclusion Criteria: * Women who are pregnant, lactating/nursing or plan to become pregnant * Previous radiation therapy to the area to be treated with radiation therapy * Receiving palliative radiation therapy * Unhealed or infected surgical sites in the irradiation area * Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan (tamoxifen/aromatase inhibitor allowed) * Use of oral corticosteroids or topical corticosteroids in the irradiation area * Use of Erbitux * Autoimmune disease * Skin disease in target irradiation area * Smoker * Known allergy to the standard of care or ingredients in KeraStat Cream